(CercleFinance.com) – Lysogene shares rose sharply on the Paris Stock Exchange on Wednesday after the biopharmaceutical company signed a licensing agreement with the Weizmann Institute of Science, an Israeli research institute.
The specialist in diseases of the nervous system specifies that this partnership must relate to the development of a gene therapy in the treatment of Gaucher and Parkinson’s diseases associated with mutations of the GBA1 gene.
In effect, Lysogene exercised its option to take out an exclusive worldwide license from Yeda, the commercial entity of the Weizmann Institute of Science, for the development and commercialization of a drug candidate.
In its press release, the company highlights the first “promising” results obtained by the teams of Professor Anthony Futerman, with the aim of deepening them in additional preclinical studies.
The cost of these preclinical studies will have no impact on the cash flow horizon, specifies Lysogene, whose share price increased by 2.8% following this announcement.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
